Pterostilbene

Pterostilbene occurs in blueberries and in Pterocarpus marsupium heartwood. Structurally it is resveratrol with two hydroxyl groups replaced by methoxy groups.

That substitution changes its pharmacokinetics. In rats, oral pterostilbene reaches roughly 80% bioavailability against roughly 20% for resveratrol, because the methyl groups resist the liver's glucuronidation machinery [1]. A follow-up study in human liver microsomes confirmed slower glucuronidation and a lower intrinsic clearance rate for pterostilbene, plus a sex difference in the enzymes involved [2]. Neither study measured a health outcome. They measured how long the compound stays detectable in blood.

The one placebo-controlled human RCT that tested pterostilbene against a clinical endpoint is a mixed result, not a clean win. Riche and colleagues gave 80 adults with elevated cholesterol either 250 mg/day pterostilbene, a lower dose with grape extract, or placebo for 6-8 weeks. The high-dose group's systolic blood pressure dropped 7.8 mmHg (p<0.01) and diastolic dropped 7.3 mmHg (p<0.001) versus placebo. But LDL cholesterol rose 17.1 mg/dL (p=0.001) in the pterostilbene-alone arm [3]. A compound lowering blood pressure while raising LDL in the same trial is not a therapeutic slam dunk; it is a trade-off that a seller's page will not headline.

Animal lifespan data exist but are thin and organism-limited. In Drosophila melanogaster, 100 μM dietary pterostilbene increased mean lifespan by 12% in males and 20% in females; the higher 200 μM dose shortened lifespan in both sexes, a reminder that more is not automatically better [4]. There is no mouse lifespan study run through a rigorous multi-lab protocol like the NIA Interventions Testing Program, and no human trial measuring any aging biomarker.

Blueprint does not list pterostilbene among Bryan Johnson's current supplements; third-party breakdowns of his roughly 74-item stack show resveratrol, not pterostilbene, in that slot. That absence undercuts the common marketing claim that self-experimenters have quietly swapped one stilbenoid for the other.

The mechanistic story for the whole stilbenoid class, sirtuin activation, took a direct hit from Pacholec and colleagues at Amgen, who showed that resveratrol and several synthetic sirtuin activators only activate SIRT1 in assays using a fluorescently tagged peptide substrate. Against full-length, untagged protein, no activation occurred [5]. That finding targets resveratrol specifically, but pterostilbene has never generated independent mechanistic data strong enough to stand apart from the same critique, since its proposed mode of action borrows directly from resveratrol's.

What this leaves is a compound with genuinely better rodent and in vitro pharmacokinetics than its parent molecule, one small human RCT with a mixed cardiovascular signal, and a fly lifespan study that does not generalize to mammals. Better absorption is a real, measured property. It is not evidence that pterostilbene extends healthy human life.

Products with this: Pterostilbene